Another batch of blood pressure drugs recalled over traces of cancer-causing chemical
Last summer, it emerged valsartan produced in China was contaminated with a carcinogen called NDEA, prompting a global recall. Now, the same has happened with an Indian manufacturer. (Source: the Mail online | Health)
Source: the Mail online | Health - January 3, 2019 Category: Consumer Health News Source Type: news
FDA expands recall on blood pressure drug valsartan due to probable carcinogen
The FDA is expanding a recall of a popular blood pressure drug over concern it may contain an unwanted ingredient that can cause cancer. Aurobindo Pharma says it is voluntarily recalling tablets with the ingredient valsartan because it found trace amounts of a substance known as NDEA. Recalls of contaminated valsartan products started in July and involve seven different companies. Dr. Tara Narula joins "CBS This Morning" with more on the latest recall. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 3, 2019 Category: Consumer Health News Source Type: news
FDA issues new recall for blood pressure meds containing valsartan
A voluntary recall has been issued for a blood pressure medication due to concerns it contains small amounts of carcinogens called N-nitrosodiethylamine. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 2, 2019 Category: Consumer Health News Source Type: news
Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the U.S.
A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration. (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the US
A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration. (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 80 Lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP, Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity
Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. To date, Aurob...
Source: Food and Drug Administration - January 1, 2019 Category: Food Science Source Type: news
Valsartan Recall Expanded, FDA Investigating Products From Outside China
(MedPage Today) -- Other ARB manufacturers subject to FDA investigation (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 23, 2018 Category: American Health Source Type: news
Do Neprilysin Inhibitors Have a Role in Patients With CKD? Do Neprilysin Inhibitors Have a Role in Patients With CKD?
Dr Desai reviews the UK HARP-III trial, which compares the effects of sacubitril/valsartan and irbesartan on kidney function in people with CKD.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2018 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news
FDA Warns Manufacturer Involved in Valsartan Recall FDA Warns Manufacturer Involved in Valsartan Recall
FDA has notified Zhejiang Huahai Pharmaceuticals it is subject to an ongoing investigation and outlines ' serious ' manufacturing violations.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 13, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
FDA warns API manufacturer involved in valsartan recall, provides information for patients taking these medications
FDA update on the ongoing investigation into angiotensin II receptor blocker impurities, recalls and current findings. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 11, 2018 Category: American Health Source Type: news
WATCH: Recall involving blood pressure medications expanding
Drugmaker Mylan is recalling 104 lots of three medications that include Valsartan after testing found trace amounts of a carcinogen. (Source: ABC News: Health)
Source: ABC News: Health - December 8, 2018 Category: Consumer Health News Tags: WNT Source Type: news
Valsartan Blood Pressure Drug Recall Widens
The drugs were recalled because of trace amounts of an impurity, N-nitrosodiethylamine, or NDEA, which may cause cancer in humans, according to the International Agency for Research on Cancer. (Source: WebMD Health)
Source: WebMD Health - December 7, 2018 Category: Consumer Health News Source Type: news
More Blood Pressure Meds Recalled Due to Carcinogen
FRIDAY, Dec. 7, 2018 -- Over the past few months, numerous recalls of the popular heart drug valsartan have already occurred. Now, generics maker Mylan Pharmaceuticals is adding more products to the list.
The recall involves 104 lots of three... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 7, 2018 Category: General Medicine Source Type: news
Mylan Expands Recall to All Unexpired Lots of Valsartan in US Mylan Expands Recall to All Unexpired Lots of Valsartan in US
The latest recall stems from NDEA contamination and includes 26 lots of amlodipine/valsartan tablets, 51 lots of valsartan tablets, and 27 lots of valsartan/hydrochlorothiazide tablets.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths). (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 4, 2018 Category: Food Science Source Type: news
